Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 2 ... from light, for a variety of rare or complex medical conditions, such as cancer, hemophilia, pulmonary arterial hypertension, multiple sclerosis, autoimmune disorders and other ...
2009 NOV 23 ... manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and ...
2009 NOV 2 ... Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients. The decision to advance the program is based on promising data from a Phase ...
2009 NOV 1 ... to treat a variety of rare, chronic and often life-threatening diseases such as PIDD, hemophilia and other bleeding disorders, as well as shock, trauma and burns. "We are ...
2009 NOV 28 ... of human coagulation factors VIIa and IX, which are being developed for the treatment of hemophilia. GTC is also developing a portfolio of follow-on biologic monoclonal antibodies and a ...
2009 NOV 1 ... will be collecting suggested donations at the door which will go to the National Hemophilia Foundation - a charity dedicated to finding better treatments and cures for bleeding and ...
2009 NOV 16 ... We particularly look forward to further advances in our joint factor VIIa program for hemophilia which is planned to move into the clinic in the first half of 2010." "LFB ...
2009 NOV 2 ... a major international biopharmaceutical company that is a market leader in the field of hemophilia. This groundbreaking feasibility agreement is worth up to $7 million in payments that ...
2009 NOV 16 ... Care, Inc. provider (ACHC) whose services emphasize treatments for individuals with hemophilia, vWD, autoimmune neuromuscular disorders and other complex chronic conditions. ...
2009 NOV 23 ... manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and ...
2009 NOV 9 ... Novo Nordisk Inc. announced the re-launch of its changing possibilities in hemophilia™ campaign through a rebranded Web site and a new community on Facebook=AE. People ...
2009 NOV 9 ... a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB)....
2009 NOV 2 ... years were studied. The prevalence was 13.7% for HCV, 7% for HBV, and 1.7% for HIV. with hemophilia had the highest prevalence for HCV and HIV infections, and hemodialyzed patients, for ...
2009 NOV 2 ... to increase the bleed-free days from 7 to 13 days (at 35 IU/kg rFVIII) in severe hemophilia A patients. To understand the underlying mechanism, we sought to recapitulate its ...
2009 NOV 23 ... genetically modified plants (Bt corn), genetically modified animals (salmon), and hemophilia germ line and somatic gene therapy," researchers in Ljubljana, Slovenia report. ...
2009 NOV 23 ... In fact, in the U.S., more people have PKD than cystic fibrosis, sickle cell anemia, hemophilia, muscular dystrophy, Down's syndrome and Huntington's Disease - COMBINED! PKD causes ...
